Ifosfamide
ایفوسفامید
🎗️ Antineoplastic And Immunomodulating AgentsAlkylating agent
Market / country: 🇺🇸 USA
Ifex (US)
🧮 Dose calculator
Testicular cancer · Regimen source: FDA Ifosfamide · 2.2
- • Only under an oncologist in an equipped centre. Calculator = label mg/m² × BSA (Mosteller); protocol, cycle interval and adjustment for CBC and renal/hepatic function rest with the oncology team. FDA Ifosfamide · 2.2
- • Always with mesna and at least 2 L/day hydration (haemorrhagic cystitis prevention). Infuse over at least 30 min. FDA Ifosfamide · 2.1
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to ifosfamide; urinary outflow obstruction. FDA Ifosfamide · 4
Warnings
- • Boxed warning: myelosuppression, encephalopathy (sometimes fatal), nephrotoxicity and haemorrhagic cystitis. FDA Ifosfamide · Boxed Warning
- • Cardiac and pulmonary toxicity; secondary malignancy; hepatic veno-occlusive disease; embryo-fetal toxicity; infertility. FDA Ifosfamide · 5
Formulations
- 1 g vial (also 3 g) — powder for injection 🇺🇸 USA FDA Ifosfamide · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Ifosfamide · 8.1
“Risk Summary Based on mechanism of action [see Clinical Pharmacology (12.1) ] , and human and animal data (see Data) , Ifosfamide for Injection can cause fetal harm when administered to a pregnant woman.”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Ifosfamide · 8.2
“Because of the potential for serious adverse events, and the tumorigenicity shown for ifosfamide in animal studies, advise women not to breastfeed during treatment with Ifosfamide for Injection and for one week after the last dose.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Ifosfamide · 8.4
“Safety and effectiveness have not been established in pediatric patients.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Ifosfamide · 8.5
“Because elderly patients are more likely to have decreased renal function, closely monitor for adverse reactions and monitor renal function as clinically indicated.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Ifosfamide · 8.3
“Contraception Females Advise female patients of reproductive potential to use effective contraception during treatment with Ifosfamide for Injection and for 12 months after the last dose.”
🔗 Reference links
- FDA (approval record)NDA019763
- DailyMed (FDA label)FDA Ifosfamide
- MedlinePlus (NIH)Ifosfamide Injection
- WHO ATC/DDDL01AA06
- Darooyab (Iran)Ifosfamide
🇮🇷 Registered in Iran Darooyab · G-1015/Ifosfamide
Dosage forms with Iranian generic codes, per Darooyab.
- 00662 · IFOSFAMIDE 1 G VIAL · ویال ایفوسفامید ۱ گرم
- 02138 · IFOSFAMIDE 2 G VIAL · ویال ایفوسفامید ۲ گرم
- 51136 · IFOSFAMIDE INJECTION, SOLUTION PARENTERAL 40 mg/1mL 25 mL · محلول تزریقی ایفوسفامید ۴۰ میلیگرم / ۱ میلیلیتر ۲۵ میلیلیتر
- 53052 · IFOSFAMIDE INJECTION, SOLUTION PARENTERAL 40 mg/1mL 50 mL · محلول تزریقی ایفوسفامید ۴۰ میلیگرم / ۱ میلیلیتر ۵۰ میلیلیتر
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Ifosfamide · 3FDA Ifosfamide · 2.2FDA Ifosfamide · 2.1FDA Ifosfamide · 4FDA Ifosfamide · Boxed WarningFDA Ifosfamide · 5FDA Ifosfamide · SPL approval / marketing categoryFDA Ifosfamide · 8.1FDA Ifosfamide · 8.2FDA Ifosfamide · 8.4FDA Ifosfamide · 8.5FDA Ifosfamide · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1015/Ifosfamide
- Clinical review⚠ Unverified